Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A recent book chapter reviews psilocybin's potential to alleviate psychological distress in cancer patients, including anxiety, depression, and existential distress. The hallucinogen treatment model has been shown to induce mystical or spiritual experiences, leading to improved psychological, spiritual, and existential well-being.
Glazer aims to develop targeted chemotherapeutic approach for various cancer types using ruthenium-based compounds activated by light. The compounds have shown up to 200 times increased toxicity and potency compared to cisplatin, a widely used platinum-based cancer drug.
Silibinin kills UVA-damaged cells, protecting against DNA damage. It also protects human skin cells from UVB radiation by increasing expression of interleukin-12, promoting cell repair.
A team of researchers at UC Irvine has discovered a rare and promising binding site on the mutant p53 protein that can be targeted by cancer-fighting drugs. This finding may lead to the development of a universal treatment approach for multiple types of cancers, including those of the lung and breast.
Researchers at Yale University have defined the genetic landscape of uterine serous carcinoma (USC), a chemo-resistant form of endometrial cancer. The study identifies three previously unknown genes that play a role in tumor growth and development, offering new avenues for personalized therapy.
Researchers found that phenformin, a derivative of metformin, decreased tumor size and increased survival in mice with advanced stage lung tumors lacking LKB1 gene. Early treatment with phenformin causes slower tumor progression and increased survival for patients with non-small cell lung cancer.
A new study by Wake Forest Baptist researchers found that emotional stress can reduce the effectiveness of prostate cancer therapies and accelerate tumor growth. Stress-induced activation of a cell signaling pathway may lead to a vicious cycle of stress and cancer progression.
A new patent issued for an experimental compound RTX, which represents a potential new class of drugs to alleviate intractable pain. The method patent covers intrathecal administration of RTX, promising to improve lives of people with severe pain.
A recent study found that stress can accelerate prostate cancer development in mice, with adrenaline blocking cancer cell death. Conversely, drugs that inhibited adrenaline signaling ablated the effect of stress on prostate cancer. This suggests that beta-blockers could enhance the effectiveness of anti-cancer therapies.
Scientists at Nottingham University are part of a €18m European-wide project using high-tech laser technology to study how drugs interact with cells. They aim to design more effective treatments for chronic illnesses like cancer and asthma by understanding how drug molecules bind and unbind from proteins.
A landmark study published in Annals of the Rheumatic Diseases found that lupus patients taking immunosuppressive medications do not have a significantly increased risk of developing lymphoma. The study involved nearly 5,000 cancer-free lupus patients and found no clear association between disease activity and lymphoma risk.
Researchers found pomalidomide provided a minimal or better response for 42% of patients with disease relapsed after treatments. The study demonstrated 'encouraging activity with manageable toxicity', paving the way for phase II studies and potential FDA approval.
A new drug called calmangafodipir has been developed to protect healthy cells from side effects of cancer treatments while enhancing the anti-tumor effect. The compound was derived from a contrast media used in magnetic resonance scans and shows promise in reducing white blood cell counts and preventing infections.
A novel cancer drug called sabutoclax appears to selectively target hard-to-reach leukemia stem cells that overexpress pro-survival protein forms. The findings suggest that pan-BCL2 inhibition may be critical for eradicating cancer stem cells in CML, and could also be beneficial for treating solid tumor cancers.
A study analyzing over 25,000 message board posts found that breast cancer survivors frequently discuss troublesome side effects from aromatase inhibitors, leading some to discontinue or switch therapies. The findings have broad implications for promoting proper adherence and informing patient-to-patient discussion online.
A University of Colorado Cancer Center study found that SPARC acts as an anti-inflammatory drug, reducing tumor growth and metastasis in bladder cancer. The protein is produced by healthy tissue to mute tumors, but aggressive cancers suppress its production, leading to faster disease progression.
Scientists have developed a new method to produce large amounts of the promising anti-cancer substance AMF-26, which targets the Golgi apparatus in cells. The synthetic version of AMF-26 shows equal effectiveness as its natural counterpart in laboratory tests.
Researchers at University College London have developed a method to render carbon nanotubes safe for use in biomedical applications. By chemically modifying and shortening the nanotubes, they can eliminate their toxic properties and make them suitable for direct transport into cells.
A recent study by Massachusetts General Hospital and Boston Health Care for the Homeless Program found that drug overdose deaths have surpassed HIV as the leading cause of death among homeless adults in Boston, with a significant increase in opioid-related overdoses. The study highlights the dire need to address the epidemic of drug ov...
Researchers found that blocking a particular pathway in cancer cells makes it easier for common drugs to annihilate tumors. By targeting this pathway, scientists aim to enhance the impact of current therapies and design new drugs to disrupt it.
A research team at Plymouth University has identified a new group of growth factor receptors that signal to brain tumors, which are over-expressed and activated in certain tumors. The study shows that by interfering with the activation, tumor cells can be corrected, paving the way for non-surgical therapies.
A gene called NEK2 promotes drug resistance in cancer, leading to faster growth and poorer patient outcomes. The finding may improve diagnostic and prognostic tools for cancer care.
Researchers at UGA have discovered a little-studied part of protein kinases that controls their function, promising to help improve existing drugs for life-threatening diseases such as cancer, diabetes, and Alzheimer's. The discovery may lead to new therapies and modifications to existing drugs, boosting their effectiveness.
Researchers found three distinct subtypes of non-Hodgkin's lymphoma, each more aggressive than the next, with varying levels of abnormal DNA methylation. This study suggests that epigenomic abnormalities play a significant role in cancer development and progression.
A Michigan State University study found that many cancer patients struggle to follow complex chemo prescriptions, leading to poor adherence and reduced treatment efficacy. The researchers suggest an automated calling system could help patients take their drugs properly.
Herbal and complementary medicines can effectively treat postmenopausal symptoms without the risks associated with hormone replacement therapy. Soy, red clover, and black cohosh have been shown to ease hot flush symptoms and other menopausal issues, making them viable alternatives for women seeking non-pharmacological treatment options.
A new study found that fingolimod, a multiple sclerosis drug, could potentially eliminate or reduce the progression of colitis-associated cancer by decreasing inflammation and blocking key signaling molecules. The researchers used animal models to demonstrate the efficacy of the drug in reducing CAC development and progression.
Researchers found that drug-resistant melanoma tumors can be controlled by using an on-again, off-again treatment schedule. This approach may prolong the effectiveness of the drug for people with late-stage disease.
A new study proposes a possible pathway to benefit from drugs for lung cancer prevention by identifying microRNA-34c as a surrogate endpoint. Changes in its expression six months after treatment correlate with benefit from the drug, potentially speeding up the pace of discovery and bringing new agents to market.
A Mayo Clinic-led study found that a combination of pazopanib and paclitaxel slows anaplastic thyroid cancer (ATC) by 50% in animal models. Researchers also observed marked tumor shrinkage in a human patient with metastatic ATC.
A large study of 263,925 adults found that drinking more than four cans of soda per day increased the risk of depression by 30%, compared to those who drank no soda. Conversely, drinking four cups of coffee per day was associated with a 10% lower risk of depression.
Researchers at Virginia Commonwealth University discovered that gene mda-9/syntenin regulates angiogenesis, a process responsible for forming new blood vessels in tumors. IGFBP-2, found to be elevated in most cancers, may serve as a novel biomarker for disease progression.
Researchers have identified the importance of Plvap/PV1 gene in forming endothelial caveolae diaphragms, which maintain basal permeability and homeostasis of blood plasma. The study found that PV1 is crucial for the survival of vascular endothelial cells and preventing protein loss.
Researchers at UNC School of Medicine identified polycomb-like proteins as key regulators in stem cell development and cancer. The study found that these proteins interact with epigenetic signals to control gene expression, implications for both stem cell biology and cancer development.
A national study by St. Jude Children's Research Hospital found that a drug shortage led to a significant increase in cancer relapse rates among pediatric patients with Hodgkin lymphoma. The study revealed an estimated two-year cancer-free survival rate of 88% for patients treated with mechlorethamine, compared to 75% for those treated...
A national drug shortage has been linked to a higher rate of relapse among children and teenagers with Hodgkin lymphoma. The study found that estimated two-year cancer-free survival fell from 88% to 75% after the drug cyclophosphamide was substituted for mechlorethamine.
Researchers analyzed over 400 patient records to find that the proportion of early-stage lung cancer cases identified by CT scans increased by almost 50% during a recent 10-year period. However, only half of these cases would meet criteria for lung cancer screening under existing guidelines.
Researchers at the University of Manchester have discovered a protein that enables cancer cells to resist MEK inhibitors, a common treatment for melanoma. By targeting this protein, SMURF2, with a combination of MEK inhibitors and reduced doses, sensitivity to the drug can be significantly increased.
A new study found that budding yeast can be a good model system to study KP1019, an anti-cancer drug. KP1019 was shown to cause cell death and delay proliferation in yeast cells, likely due to DNA damage.
Researchers identified miR-181a as a molecule linked to aggressive breast cancer forms. Elevated levels of miR-181a prevented metastasis and extended mouse lifespans in test models.
Pitt Cancer Institute researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line that could offer new hope for drug treatment to destroy cancer cells. The findings may lead to the development of adjuvant chemotherapy drugs that will improve patient survival rates.
A preclinical study suggests that inhibiting mTORC1 with everolimus can suppress Myc-driven tumor initiation and growth. Everolimus caused tumor regression by inducing cellular senescence, rather than apoptosis.
Researchers have isolated cancer stem cells from kidney tumors that lead to Wilms' tumours, a type of cancer typically found in the kidneys of young children. These cancer stem cells can be targeted with an antibody drug, providing a potential new approach for treating this disease.
Researchers discovered that genetic mutations are only one piece of the puzzle, and biological factors and cell behavior contribute to tumour growth and therapy failure. The team found that some cancer cells were responsible for keeping cancer growing, while others were transient and stopped within days.
Dana-Farber Cancer Institute scientists identify EZH2 as a key player in prostate cancers that no longer respond to hormone-blocking treatments. The researchers suggest that drugs targeting EZH2's unexpected function could be an effective new treatment strategy for these aggressive cancers.
Researchers at the University of Alberta have identified a rare type of cancer suppressor that can trigger cell death when targeted. By inactivating this gene, cancer cells are destroyed while healthy cells remain intact.
A new screening approach identified potential anticancer drug combinations that target RAS and BRAF mutations in melanoma. The study found that pairing cholesterol-reducing drugs with cyclin-dependent kinase inhibitors showed efficacy against RAS-driven melanomas.
A new Dream Team project, Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy, aims to expand and optimize combinations of two novel immunotherapies. The team will unite laboratory and clinical efforts to develop durable responses in patients suffering from various types of cancer.
Researchers discovered that FAIM can affect cancer cell proliferation and silencing its expression destroys myeloma cells. Higher levels of FAIM correlate with poorer survival outcomes, making it a useful biomarker for multiple myeloma patients.
Researchers identified a previously unidentified virus in raccoons that may be contributing to the development of brain tumors. The study found that this virus, dubbed raccoon polyomavirus, is present in all affected animals and may play a role in tumor formation.
Recent advancements in lung cancer treatment focus on targeting specific genetic mutations, resulting in improved patient response rates (70-80%) compared to traditional chemotherapies. However, challenges remain in securing funding for clinical trials and staying ahead of the disease's rapid mutation rate.
Consumers believe that life-saving products like vaccines and cancer medications are priced based on need rather than profit. This perception can lead to an increased perceived health risk when prices are low, even if the product is still necessary.
A new study reveals that the SIRT6 gene plays a critical role in suppressing cancer growth by repressing aerobic glycolysis and inhibiting Myc activity. The loss of SIRT6 protein in mice increases tumor size and aggressiveness, highlighting its potential as a tumor suppressor.
Researchers have genetically engineered algae to produce a complex and expensive human therapeutic drug used to treat cancer. The method could be used to make novel complex designer drugs that can't be produced in any other systems, potentially driving down prices dramatically.
Boston College researcher Marc-Jan Gubbels is working on new drugs to prevent toxoplasmosis in cancer patients with weakened immune systems. The goal is to trap the parasite within cells and prevent it from attacking, which could lead to the development of more effective treatments with fewer side effects.
A new class of drugs has been shown to reduce the risk of graft-vs.-host disease, a deadly side effect of lifesaving bone marrow transplants, by half. The study used vorinostat, a cancer drug with anti-inflammatory effects, and found it safe and tolerable for patients undergoing reduced-intensity bone marrow transplants.
A Phase II clinical trial found that over a third of high-risk leukemia patients responded to the experimental new drug quizartinib, experiencing complete remission and potentially life-saving bone marrow transplants. Many participants who did well with the drug had failed to respond to prior therapies.
Researchers block DNA repair pathway in leukemia stem cells by targeting protein RAD52, which is crucial for fixing genetic mistakes. This approach may lead to a new strategy to overcome drug resistance in cancer patients.
Scientists discovered blocking a specific protein makes tumors more vulnerable to treatment in mice, hinting at potential new therapies for humans. Researchers are now exploring inhibitors of the protein, which could boost cancer drugs' effectiveness.
Researchers found that Mesupron combined with Capecitabine significantly extended progression-free survival for patients with metastatic breast cancer to 8.3 months, nearly twice that of those taking Capecitabine alone. The study also showed improved results in previously treated patients.